FDA clears SonaCare HIFU prostate device, prompts Edap to yank de novo, go for 510k
SonaCare said it won FDA pre market approval for its high intensity focused ultrasound device designed to treat prostate cancer, causing competitor EDAP (NSDQ:EDAP) to yank the de novo application for its Ablatherm HIFU.
SonaCare said its Sonablate 450 will be available in the U.S. this October.
“The FDA regulatory authorization to market Sonablate in the U.S. is a milestone for non-invasive prostate care and a tremendous gain for men’s health. Men all over the world, in the more than 49 countries where it has already been authorized for use, have had access to this technology for prostate ablation. There are nume...
Source: Mass Device - October 15, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Food & Drug Administration (FDA) Oncology Pre-Market Approval (PMA) Regulatory/Compliance EDAP TMS SA SonaCare Medical Source Type: news
Brachytherapy Benefits in High-Risk Prostate CancerBrachytherapy Benefits in High-Risk Prostate Cancer
Brachytherapy after external beam radiotherapy (EBRT) doubles the chance of progression-free survival at 9 years when compared with EBRT alone. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 28, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Brachytherapy Boosts Survival in Inoperable Endometrial CancerBrachytherapy Boosts Survival in Inoperable Endometrial Cancer
Women with inoperable early-stage endometrial cancer survive longer if their treatment includes brachytherapy rather than external beam radiotherapy alone. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 27, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Prostate cancer patients who receive permanent radiotherapy implants twice as likely to be free of cancer after five years
Results from a randomised controlled trial to compare the use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer show that the men who received brachytherapy were twice as likely to be cancer-free five years later. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 27, 2015 Category: Science Source Type: news
Permanent radiotherapy implants reduce risk of prostate cancer recurrence after 5 years
(European Society for Radiotherapy and Oncology (ESTRO)) Results from a randomized controlled trial to compare the use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer show that the men who received brachytherapy were twice as likely to be cancer-free five years later. The research will be presented at the 3rd ESTRO Forum in Barcelona, Spain, (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 26, 2015 Category: Cancer & Oncology Source Type: news
Brachytherapy improves survival for inoperable early stage endometrial cancer
Women who have early stage endometrial cancer and are inoperable tend to live longer if they have been treated with brachytherapy with or without external beam radiation, according to new research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 26, 2015 Category: Science Source Type: news
Brachytherapy improves survival for inoperable early stage endometrial cancer
(European Society for Radiotherapy and Oncology (ESTRO)) Women who have early stage endometrial cancer and are inoperable tend to live longer if they have been treated with brachytherapy with or without external beam radiation, according to new research to be presented at the 3rd ESTRO Forum in Barcelona, Spain. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 25, 2015 Category: Cancer & Oncology Source Type: news
The 6 Injustices of Thyroid Cancer
Imagine if your best friend -- the one who deserves one hell of a co-pay for the psych-worthy advice she doles out on a daily basis (with love and/or or a swift kick in the butt, as needed) suddenly couldn't speak.
My lifeline, Jill Gurfinkel, had a paralyzed vocal cord for what seemed like forever. Not from cheering for her then 7-year-old son at his hockey game or yelling at him to eat his vegetables or even from litigating in court (I don't mess around; my chief counsel is a badass lawyer). The only thing that has ever robbed her of her voice was thyroid cancer.
In Cindy Finch's recent HuffPost blog, "The 6 Injustice...
Source: Healthy Living - The Huffington Post - February 3, 2015 Category: Consumer Health News Source Type: news
Patients treated with radiation therapy who have tumors in left breast have comparable overall survival to those with tumors in right breast
Tumor laterality (left-side vs. right-side) does not impact overall survival in breast cancer patients treated with breast-conserving surgery and adjuvant external beam radiation therapy, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 20, 2014 Category: Science Source Type: news
Patients who have left breast tumors have comparable OS to those with right breast tumors
(American Society for Radiation Oncology) Tumor laterality (left-side vs. right-side) does not impact overall survival in breast cancer patients treated with breast-conserving surgery and adjuvant external beam radiation therapy, according to a study published in the Oct. 1, 2014 issue of the International Journal of Radiation Oncology Biology Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 20, 2014 Category: Cancer & Oncology Source Type: news
Prostate cancer patients surveyed 5 years after vessel-sparing RT report preserved sexual function
(American Society for Radiation Oncology) A comparison of five-year sexual function outcomes, as reported by patients treated with external beam radiotherapy versus combination external beam radiotherapy plus brachytherapy, indicates that the utilization of vessel-sparing radiation therapy makes cure possible without compromising long-term sexual function, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 16, 2014 Category: Global & Universal Source Type: news
Convenient, less expensive, but possibly riskier new prostate cancer treatment: SBRT
A faster and less expensive form of radiotherapy for treating prostate cancer may come at a price, according to a new study by Yale School of Medicine researchers - a higher rate of urinary complications.The standard external beam radiation therapy for prostate cancer is called intensity modulated radiation therapy (IMRT). Stereotactic body radiotherapy (SBRT) is a newer treatment that delivers a greater dose of radiation per treatment than IMRT. As a result, patients receiving SBRT can complete an entire course of treatment in one to two weeks, compared to seven to nine weeks for IMRT. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 12, 2014 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
MammoSite Breast Brachytherapy
MammoSite breast brachytherapy is an alternative radiation treatment to external beam radiation of the breast. MammoSite breast brachytherapy takes 5 days to completely treat early stage breast cancer with radiation after a lumpectomy. Learn more about MammoSite breast brachytherapy here. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 28, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Mixed Results for Brachytherapy in Breast Cancer (CME/CE)
(MedPage Today) -- Older breast cancer patients had an increased rate of subsequent mastectomy if they received brachytherapy instead of external-beam radiation therapy after lumpectomy but fared better than patients who received no radiation, investigators reported. (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - February 7, 2014 Category: Surgery Source Type: news
EBRT reduces risk of subsequent mastectomy in patients with invasive breast cancer
(American Society for Radiation Oncology) Standard external beam radiation therapy (EBRT) provided a higher breast preservation rate than brachytherapy in women age 66 and older with invasive breast cancer, according to a study published in the Feb. 1, 2014, print edition of the International Journal of Radiation Oncology*Biology*Physics, the official scientific journal of the American Society for Radiation Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 29, 2014 Category: Cancer & Oncology Source Type: news
